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Background. Streptococcus pneumoniae coinfection with influenza results in synergistic lethality, but there are limited data on 
pneumococcal coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Methods. Public Health England conducts invasive pneumococcal disease (IPD) and SARS-CoV-2 surveillance in England. 
IPD trends during 2000/2001–2019/2020 epidemiological years were analyzed and cases during February–June 2020 linked with 
laboratory-confirmed SARS-CoV-2 infections. Multivariable logistic regression was used to assess risk factors for death.
Results. IPD incidence in 2019/2020 (7.6/100  000; n = 3964) was 30% (IRR, .70; 95% CI, .18–2.67) lower compared with 
2018/2019 (10.9/100 000; n = 5666), with large reductions observed across all age groups during March–June 2020. There were 
160 886 SARS-CoV-2 and 1137 IPD cases during February–June 2020, including 40 IPD/coronavirus disease 2019 (COVID-19) 
co-infections (.025% [95% CI, .018–.034] of SARS-CoV-2 infections; 3.5% [2.5–4.8] of IPD cases), 21 with COVID-19 diagnosed 
3–27 days after IPD, and 27 who developed COVID-19 ≥28 days after IPD. Case-fatality rates (CFRs) were 62.5 (25/40), 47.6% 
(10/21), and 33.3% (9/27), respectively (P < .001). In addition to an independent association with increasing age and serotype group, 
CFR was 7.8-fold (95% CI, 3.8–15.8) higher in those with IPD/COVID-19 coinfection and 3.9-fold (95% CI, 1.4–10.7) higher in pa-
tients who developed COVID-19 3–27 days after IPD compared with patients with IPD only.
Conclusions. Large declines in IPD were observed following COVID-19 lockdown. IPD/COVID-19 coinfections were rare but 
associated with high CFR, mainly in older adults. The rarity, age and serotype distribution of IPD/COVID-19 coinfections do not 
support wider extension of pneumococcal vaccination.
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Viral respiratory tract infections usually predispose to secondary 
bacterial infections, which are associated with high morbidity and 
mortality, especially during pandemics [1, 2]. The association be-
tween Streptococcus pneumoniae and influenza, for example, is well 
described and has important implications because there are effec-
tive vaccines against the major pneumococcal serotypes causing 
invasive disease [3, 4]. Coronavirus disease 2019 (COVID-19), the 
disease caused by severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2), typically manifests as a respiratory tract infec-
tion and presents with fever and cough [5], which may progress 
to severe pneumonia, multiorgan failure, and death, especially 
in older adults and those with underlying comorbidities [6–8]. 
Bacterial coinfection with COVID-19, however, appears to be 
uncommon [9–11]. A meta-analysis of mainly small case series 
estimated that 3.5% of patients with COVID-19 had a bacterial 
coinfection and 14.3% had a secondary bacterial infection [12]. 
These infections occurred mainly in intensive care patients, with 
no particular pathogen predominating [12].
In the United Kingdom, the first imported cases of COVID-
19 were reported at the end of January 2020 and endemic trans-
mission in late February, with cases increasing rapidly from early 
March and peaking in mid-April before declining [13]. In re-
sponse, the United Kingdom implemented national lockdown 
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measures on 23 March 2020 with a stay-at-home order for all 
but essential travel and work [14]. The reduced social mixing re-
sulting from the lockdown is likely to have affected the incidence 
of many infectious diseases in addition to SARS-CoV-2 [15].
In England, Public Health England (PHE) is responsible for 
enhanced national surveillance of invasive pneumococcal disease 
(IPD) and COVID-19. We used multiple national surveillance 
data sources to investigate the impact of the COVID-19 pandemic 
and the consequent lockdown on IPD to estimate the risk of SARS-
CoV-2 and IPD coinfection and to describe the demographics, 
responsible serotypes, comorbidity status, clinical features, and 
outcomes of patients with IPD/COVID-19 coinfection during 
the first wave of the COVID-19 pandemic in England. We also 
assessed the potential role of pneumococcal vaccines in reducing 
IPD morbidity and mortality during the COVID-19 pandemic.
METHODS
The UK Pneumococcal Immunization Program
In the United Kingdom, the 13-valent pneumococcal conjugate 
vaccine (PCV13) replaced the 7-valent vaccine (PCV7) in 2010 
and, until recently, was offered to infants at 8 and 16 weeks of 
age, with a booster at 1 year [16]. From 1 January 2020, a re-
duced infant 1 + 1 infant immunization schedule at 12 weeks 
and 1 year was implemented in the United Kingdom [17]. In 
addition, children aged 2 years or older and adults with under-
lying comorbidities that predispose them to IPD and all adults 
aged 65 years and older are offered a single dose of 23-valent 
pneumococcal polysaccharide vaccine (PPV23) [18].
National Surveillance
Public Health England conducts national IPD surveillance in 
England [19]. Briefly, hospital laboratories electronically report 
invasive pneumococcal infections to PHE using the Second-
Generation Surveillance System (SGSS) and submit pneumo-
coccal isolates to the PHE national reference laboratory for 
confirmation and serotyping. Confirmed cases are followed up 
by requesting the general practitioner to complete a surveillance 
questionnaire on immunization history, comorbidities, clinical 
presentations, complications, and outcomes. A final reconciled 
database containing laboratory-confirmed IPD cases during 
the 2000/2001 to 2019/2020 epidemiological years (July to June, 
20 years) was used for this analysis.
The SGSS also contains reports of laboratory-confirmed 
SARS-CoV-2 infections in England. In the United Kingdom, 
SARS-CoV-2 tests are performed through different routes called 
“Pillars” [20]. In Pillar 1, SARS-CoV-2 real-time reverse tran-
scription–polymerase chain reaction (RT-PCR) tests are under-
taken on respiratory swabs by PHE laboratories and National 
Health Service (NHS) hospitals for those with a clinical need 
and for healthcare and care workers. This group was prioritized 
for SARS-CoV-2 testing by RT-PCR during the first pandemic 
wave, with minimal virus testing in the community. Positive 
results from Pillar 1 testing were linked with IPD cases from 
1 February to 30 June 2020 (5 months) using full name, sex, 
birth date, reporting hospital, and site and date of sample. 
The IPD and SARS-CoV-2 cases confirmed in June 2020 were 
linked with cases until 31 July 2020. Deaths were confirmed 
using the personal demographic service, an online national 
database that holds demographic data and death status for 
NHS patients.
Definitions
Invasive pneumococcal disease was defined as isolation of 
S.  pneumoniae from a normally sterile site. SARS-CoV-2 
infection was confirmed by RT-PCR on an upper respira-
tory tract swab or a lower respiratory tract sample such 
as bronchioalveolar lavage (BAL). In England, blood cul-
tures are invariably taken in hospital settings (emergency 
department or hospital ward) when a bacterial infection is 
suspected. During the first wave of the pandemic, patients 
attending a hospital for any illness were routinely tested 
for SARS-CoV-2 infection at presentation and, if hospi-
talized, when COVID-19 was suspected. Coinfection was 
defined as a positive pneumococcal culture taken from a 
sterile site within 2 days of a positive SARS-CoV-2 RT-PCR 
result. Secondary infection was defined as a laboratory-
confirmed infection in a sample taken 3–27 days after the 
first infection.
Statistical Analysis
Data were analyzed using Stata v.15.0 (StataCorp, College 
Station, TX). Corrected annual IPD incidence by epidemiolog-
ical year and serotype group (PCV13, PPV23, non-PPV23) were 
calculated as previously described, adjusting for missing pro-
portion of isolates serotyped and missing age [19], using popula-
tion denominators from the Office for National Statistics (www.
statistics.gov.uk). We estimated the proportion of coinfections 
and secondary infections in individuals with IPD and SARS-
CoV-2 infection between 1 February and 30 June 2020 (with 
cases diagnosed until the end of July 2020) and compared the 
demographics, clinical features, and outcomes of patients who 
had separate episodes of IPD and COVID-19 (≥28 days apart). 
Case-fatality rates (CFRs) were calculated for deaths within 
30 days of the last IPD or SARS-CoV-2 infection. Data that did 
not follow a normal distribution are presented as medians with 
interquartile range and compared using the Mann-Whitney U 
test. Categorical variables are reported as proportions with bi-
nomial 95% confidence intervals (CIs) and compared using the 
chi-square or Fisher’s exact test as appropriate. A multivariable 
logistic regression model was fitted to assess risk factors asso-
ciated with 30-day CFRs and included age group (<16, 16–64, 
65–84, and ≥85  years), sex, ethnicity (White, Black, Asian, 
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infection) comparing to the baseline group of IPD-only cases 
during February–June 2020.
RESULTS
There were large declines in IPD incidence across all age groups 
during 2019/2020 in England (Figure  1). Most of the decline 
was observed between March and June 2020. The incidence 
of IPD in 2019/2020 (3964 cases, 7.6/100 000) was 30% (inci-
dence rate ratio [IRR], .70; 95% CI, .18–2.67) lower compared 
with 2018/2019 (5666 cases, 10.9/100  000); this decline was 
seen across the individual age groups, including children aged 
less than 16 years (2.1/100 000; IRR, .71; 95% CI, .11–10.00), 
16- to 64-year-olds (4.5/100 000; IRR, .65; 95% CI, .11–3.79), 
65- to 84-year-olds (17.6/100 000; IRR, .72; 95% CI, .29–1.74), 
and individuals aged 85 years and older (54.9/100 000; IRR, .69; 
95% CI, .42–1.76). The distribution of pneumococcal serotypes 
causing IPD during 2019/2020 was similar to previous years 
and, of the 3693 (93%) isolates with serotype information, in-
cluded 19.7% PCV13 (n = 729), 56.0% PPV23 (n = 2068), and 
24.1% non-PPV23 (n = 892) serotypes.
Invasive Pneumococcal Disease/COVID-19 Coinfections
Between 1 February 2020 and 30 June 2020, there were 160 886 
laboratory-confirmed SARS-CoV-2 infections reported 
through Pillar 1 testing in a healthcare setting (Figure 2) and 
1137 laboratory-confirmed IPD cases, with 88 having both IPD 
and COVID-19 and including 40 IPD/COVID-19 coinfections 
predominantly during the early part of the pandemic (Table 1, 
Figure 3). The latter included 1 elderly patient who had visited 
the emergency department after a fall and who was asympto-
matic but had screened positive for SARS-CoV-2. This patient 
was hospitalized 4  days later with a respiratory illness, had a 
positive blood culture for S. pneumoniae, and was included in 
the analysis as an IPD/COVID-19 coinfection case since his in-
itial SARS-CoV-2 swab result was an incidental finding.
Of the remaining 48 cases with IPD and COVID-19 diag-
nosed more than 2 days apart, an older adult with malignancy 
was first hospitalized with mild, laboratory-confirmed COVID-
19, recovered, and then developed IPD as a separate episode 
22 days later and survived. This patient was considered to have 
2 separate infections and was not included as an IPD/COVID-
19 coinfection. The remaining 47 patients had their first pos-
itive SARS-CoV-2 test at least 3 days after their blood culture 
confirming IPD was taken. This group included 15 cases who 
tested positive for SARS-CoV-2 within 3–14  days after their 
blood culture confirming IPD was taken, of whom 11 had at 
least 1 negative SARS-CoV-2 swab result since presenting to the 
hospital before subsequently testing positive for SARS-CoV-2; 
swab results were not available for the remaining 4 patients. Six 
other patients tested positive for SARS-CoV-2 at 15–27  days 
after their IPD diagnosis and the remaining 27 tested positive 
for SARS-CoV-2 infection 28 days or later after their IPD ep-
isode. The majority in the latter group had developed IPD 
during February and early March 2020, recovered from their 
illness, and then developed SARS-CoV-2 infection during the 
peak of the epidemic in April 2020.
Both IPD and SARS-CoV-2 incidence was lowest in chil-
dren during the 5-month surveillance and increased with age 
(Table 2). Coinfections with IPD/COVID-19 were identified in 
.025% (40/160 886; 95% CI, .018–.034%) of patients with con-
firmed SARS-CoV-2 infection and 3.5% of IPD (40/1137; 95% 
CI, 2.5–4.8%) cases. There were no IPD/COVID-19 coinfections 
in children. The risk of IPD/COVID-19 coinfection increased 
with age among patients with IPD but to a lesser extent than 
IPD alone or SARS-CoV-2 alone (Table 2). Hypertension and 
dementia were the most commonly reported comorbidities.
There were 35 deaths within 28 days of the last infection in 
patients who developed IPD and COVID-19, with most deaths 
occurring within 1 week of the latter infection (Figure 4). The 
CFR was highest in the coinfection group (25/40, 62.5%) com-
pared with 53.3% (8/15) in those with COVID-19 at 3–14 days 
after IPD, 33.3% for those with COVID-19 at 15–27 days after 
IPD (2/6 cases), and those with IPD and COVID-19 28 days or 
more apart (9/27 cases) (χ 2 for trend, P < .001). In addition to an 
independent association with increasing age and pneumococcal 
serotype group, death within 30  days was 3.88-fold (95% CI, 
1.41–10.65-fold) higher in patients who developed COVID-19 
at 3–27 days after IPD and 7.75-fold (95% CI, 3.80–15.82-fold) 
higher in those with IPD/COVID-19 coinfection (Table 3).
DISCUSSION
The COVID-19 pandemic and subsequent lockdown meas-
ures were associated a large decline in IPD cases in England. 
The 30% decline in IPD incidence was observed across all age 
groups and for all pneumococcal serotype groups. Among 
160  886 laboratory-confirmed SARS-CoV-2 infections con-
firmed in a healthcare setting, we found only 88 individuals who 
developed both IPD and COVID-19 during the first wave of the 
epidemic and only 40 IPD/COVID-19 coinfections. Contrary 
to our hypothesis that SARS-CoV-2 infection might predis-
pose to secondary pneumococcal infection, we found that pa-
tients were more likely to develop COVID-19 after IPD or as a 
separate episode 28 days or more after IPD. Those with IPD/
COVID-19 coinfection had very high CFRs, which decreased 
with increasing interval between the 2 infections.
Invasive Pneumococcal Disease Decline
The decline in IPD incidence occurred during March–June 2020 
when lockdown measures were implemented across the United 
Kingdom to control the spread of SARS-CoV-2, consistent with 
emerging reports of large reductions in bacterial and viral in-
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Figure 1. Corrected incidence of IPD in England by age group and serotype group, 2000–2020. The arrows indicate the timing of introduction of the 7-valent 
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countries that implemented lockdown during the COVID-19 
pandemic [15]. Interestingly, we observed significant reduc-
tions in IPD cases in older adults, including those aged 85 years 
and older, at a time when large numbers of COVID-19 cases 
and deaths were reported in these age groups [21]. The frail and 
elderly are at increased risk of both IPD and COVID-19 and 
both infections are individually associated with high CFRs in 
this vulnerable age group [18]. The inverse trend of decreasing 
IPD and increasing SARS-CoV-2 infections in older adults 
likely reflects differences in the source of infection and effi-
ciency of transmission for the 2 pathogens. In particular, young 
children are considered to be the main reservoirs and source of 
pneumococcal infections [22], and it is likely that the shielding 
of older adults, especially from children, during lockdown re-
duced their risk of IPD but not from COVID-19, which was 
mainly acquired from other adults, as evidenced in the exten-
sive COVID-19 outbreaks in nursing homes that were driven 
mainly by cross-infection between residents and staff [23].
Risk of Coinfection
We found very few pneumococcal coinfections associated 
with SARS-CoV-2 in our cohort. Interestingly, we did not 
identify any IPD/COVID-19 cases in children; since blood 
cultures are almost exclusively taken in the hospital, children 
with IPD would have been tested for SARS-CoV-2 infection 
when they presented to a hospital. This is consistent with the 
published case series, systematic reviews, and meta-analyses 
that have so far not identified any patients with SARS-CoV-2 
and pneumococcal coinfection [12]. There are limited data on 
bacterial coinfections with Middle East respiratory syndrome 
(MERS) or severe acute respiratory syndrome (SARS) [11], 
but reports of bacterial coinfections with influenza range 
between 2% and 65%, with S.  pneumoniae being the most 
common coinfecting bacteria, accounting for 35% (95% CI, 
14–56%) of infections in 1 systematic review [1]. During the 
influenza A(H1N1) pandemic, when there were no lockdown 
measures or school closures in England, data linkage similar 
to our current analysis identified pneumococcal coinfection 
rates of 8% (10/125) in children younger than 15 years, 11% 
(33/305) in 15- to 44-year-olds, 4% (33/858) in those aged 
45 years and older, and 6% (76/1288) of IPD cases [24]. There 
is currently sufficient evidence to strengthen and potentially 
expand pneumococcal vaccination to reduce the risk of sec-
ondary pneumococcal infections associated with influenza 
and particularly during influenza pandemics [3, 25]. In con-
trast, the very low risk, wide age range, and distribution of 
pneumococcal serotypes causing IPD in patients with IPD/
COVID-19 coinfections do not support wider immunization 
with any of the currently available pneumococcal vaccines. 
It is, however, important to maintain high pneumococcal 
Figure 2. Number of cases of IPD, SARS-CoV-2, and coinfections during the first peak (1 February to 30 June 2020) of the COVID-19 pandemic in England. Abbreviations: 
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immunization rates to continue to protect those who are at 
increased risk of pneumococcal disease after the lockdown 
is eased.
Additionally, the low overall risk of bacterial coinfections 
also predicates judicious use of empiric antimicrobials in pa-
tients hospitalized with COVID-19. Up to three-quarters of 




COVID-19 3–27 Days 
After IPD (n = 21)
Total (IPD and COVID-19 
Cases Within 28 Days  
of Each Other)a (n = 62)
IPD and COVID-19  
Episodes ≥28 Days 
Apart (n = 26)
All Cases With  
IPD and COVID- 
19a (n = 88)
Age, median (IQR), years 79 (58–86) 77 (66–85) 78 (58–85) 80 (67–84) 60 (42–85)
Age group, n (%)      
 16–64 years 15 (37.5) 5 (23.8) 20 (32.3) 6 (23.1) 26 (29.5)
 65–84 years 14 (35.0) 10 (47.6) 25 (40.3) 14 (53.8) 39 (44.3)
 ≥85 years 11 (27.5) 6 (28.6) 17 (27.4) 6 (23.1) 23 (26.1)
Sex, n (%)      
 Male 18 (45.0) 7 (33.3) 26 (41.9) 10 (38.5) 36 (40.9)
 Female 22 (55.0) 14 (66.7) 36 (58.1) 16 (61.5) 52 (59.1)
Ethnic group, n (%)      
 White 33 (82.5) 17 (81.0) 51 (82.3) 21 (80.8) 72 (81.8)
 Black 1 (2.5) 3 (14.3) 4 (6.5) 3 (11.5) 7 (8.0)
 Asian 5 (12.5) 1 (4.8) 6 (9.7) 1 (3.8) 7 (8.0)
 Mixed 1 (2.5) 0 (0.0) 1 (1.6) 1 (3.8) 2 (2.3)
Any comorbidity, n (%) n = 40/40 n = 21/21 n = 62/62 n = 26/26 n = 88/88
 Yes 29 (72.5) 18 (85.7) 48 (77.4) 21 (80.8) 69 (78.4)
 No 11 (27.5) 3 (14.3) 14 (22.6) 5 (19.2) 19 (21.6)
Comorbiditiesb n = 40/40 n = 21/21 n = 62/62 n = 26/26 n = 88/88
 Chronic heart disease 14 (48.3) 7 (38.9) 21 (43.8) 10 (47.6) 31 (44.9)
 Chronic respiratory 
disease
6 (20.7) 4 (22.2) 7 (14.6) 10 (47.6) 20 (29.0)
 Chronic liver disease 0 (0.0) 4 (22.2) 3 (6.3) 1 (4.8) 5 (7.2)
 Chronic renal disease 10 (34.5) 5 (27.8) 13 (27.1) 6 (28.6) 21 (30.4)
 Immunosuppressed/ma-
lignancy
5 (17.2) 5 (27.8) 10 (20.8) 7 (33.3) 18 (26.1)
 Diabetes mellitus 11 (37.9) 7 (38.9) 17 (35.4) 5 (23.8) 23 (33.3)
 Other 17 (58.6) 11 (61.1) 28 (58.3) 13 (61.9) 41 (59.4)
Clinical presentation, n (%)      
 Meningitis 1 (2.5) 0 (0.0) 1 (1.6) 1 (3.9) 2 (2.3)
 Bacteremic pneumonia 31 (77.5) 15 (71.4) 47 (75.8) 16 (61.5) 63 (71.6)
 Other/not reported 4 (10.0) 4 (19.1) 8 (12.9) 4 (15.4) 12 (13.6)
 Septicaemia 4 (10.0) 2 (9.5) 6 (9.7) 5 (19.2) 11 (12.5)
ICU admission, n (%)      
 Yes 6 (15.0) 0 (0.0) 6 (9.7) 4 (15.4) 10 (11.4)
 No 34 (85.0) 21 (100.0) 56 (90.3) 22 (84.6) 78 (88.6)
Died, n (%)      
 <28 days 25 (62.5) 10 (47.6) 35 (56.5) 9 (33.3) 44 (50.0)
 0–6 days 22 (88.0) 4 (40.0) 26 (74.3) 7 (77.8) 33 (75.0)
 7–13 days 2 (8.0) 3 (30.0) 5 (14.3) 1 (11.1) 6 (13.6)
 14–20 days 1 (4.0) 1 (10.0) 2 (5.7) 1 (11.1) 3 (6.8)
 21–27 days 0 (0.0) 2 (20.0) 2 (5.7) 0 (0.0) 2 (4.5)
Serotype group, n (%)      
 Number of isolates 
serotyped
n = 38/40 n = 18/21 n = 57/62 n = 23/26 n = 80/88
 PCV13c 5 (13.2) 2 (11.8) 8 (14.0) 5 (21.7) 13 (16.3)
 Additional PPV23d 22 (57.9) 9 (52.9) 31 (54.4) 12 (52.2) 43 (53.8)
 Non-PPV23 11 (28.9) 7 (41.2) 18 (31.6) 6 (26.1) 24 (30.0)
Abbreviations: COVID-19, coronavirus disease 2019; ICU, intensive care unit; IPD, invasive pneumococcal disease; IQR, interquartile range; PCV13, 13-valent pneumococcal conjugate vac-
cine; PPV23, 23-valent pneumococcal polysaccharide vaccine. 
aTotal includes the single case who had COVID-19, recovered, and then developed IPD as a separate episode 22 days later.
bMany patients had multiple comorbidities.
cPCV13 helps protect against the following pneumococcal serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, 18C, and 23F.
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patients hospitalized with COVID-19 in England receive em-
piric antibiotics despite the low risk of bacterial coinfections 
[9]. Unnecessary and widespread empiric antibiotic overuse can 
predispose to hospital-acquired, potentially multidrug-resistant, 
secondary gram-negative bacterial as well as fungal infections, 
which significantly increase the risk of a fatal outcome [26, 27].
In our cohort, the CFR was 62.5% in patients with IPD/
COVID-19 coinfection, which is significantly higher than 
that reported in older adults after IPD only [18] or COVID-
19 only [28], and suggests a potential synergistic effect between 
the 2 pathogens, as has been described for pneumococcal/
influenza coinfections [29]. Furthermore, in addition to the 
40 coinfections, we also identified 21 other patients who devel-
oped COVID-19 3–27 days after being hospitalized with IPD 
and 10 (47.6%) died. It is possible that at least some of these 
patients had IPD/COVID-19 coinfection, but our finding that 
11 of the 15 patients with IPD with confirmed COVID-19 at 
3–14 days after IPD had negative swabs for SARS-CoV-2 when 
they were hospitalized for IPD supports secondary and poten-
tially nosocomially acquired SARS-CoV-2 infection. This high-
lights the importance of maintaining stringent infection-control 
practices in the hospital [30, 31], especially for frail and elderly 
adults, who may be hospitalized with a minor illness but could 
succumb to hospital-acquired COVID-19 [32, 33]. Finally, the 
finding that one-third of patients who developed COVID-19 
more than 14 days after their IPD episode died within 30 days 
of their subsequent SARS-CoV-2 infection highlights the vul-
nerability of this group of patients, most of whom were elderly 
and with multiple comorbidities.
Strengths and Limitations
The strength of this study lies in the availability and rapid 
cross-linking of multiple national data sources alongside long-
term enhanced national surveillance of vaccine-preventable 
infections in England. In the United Kingdom, blood cultures 
are invariably performed in patients who present to a hospital 
with suspected invasive bacterial infection. We, therefore, only 
linked IPD cases with Pillar 1 SARS-CoV-2 tests that were 
performed in a healthcare setting because we hypothesized 
that all IPD cases would have been hospitalized and tested 
for SARS-CoV-2 infection on admission. There was also very 
limited testing for SARS-CoV-2 in the community during the 
Figure 3. Flowchart of laboratory-confirmed cases with IPD and COVID-19 between 1 February and 30 June 2020 (5 months) in England. *IPD and SARS-CoV-2 cases were 
matched up to 31 July 2020 to confirm that there were no further coinfections for those initially infected with IPD/SARS-CoV-2 in June 2020. **Included 1 elderly patient 
who visited the emergency department after a fall, was asymptomatic, and had screened positive for SARS-CoV-2 but was hospitalized with a positive blood culture for 
Streptococcus pneumoniae 3 days later due to SARS-CoV-2 infection being an incidental finding. Abbreviations: COVID-19, coronavirus disease 2019; DOB, date of birth; IPD, 
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first wave of the epidemic in England. Additionally, since un-
well individuals were more likely to have been referred directly 
to the hospital instead of being assessed in primary care, they 
were unlikely to have been tested for SARS-CoV-2 outside 
the hospital setting or prescribed oral antibiotics that might 
have resulted in negative blood cultures on admission. A lim-
itation of our analysis is that we only included patients with 
IPD and, therefore, cannot comment on the risk of noninva-
sive pneumococcal infections, such as pneumonia. Invasive 
pneumococcal disease is, however, a reliable proxy for nonin-
vasive pneumococcal disease [34]. To support this, case series 
reporting sputum cultures as well as deep tracheal cultures 
in ventilated patients have also not identified S.  pneumoniae 
in patients with COVID-19 [12], while radiological assess-
ments of patients with severe respiratory presentations have 
rarely reported evidence of secondary bacterial pneumonia 
[35, 36]. Future studies using urine serotype-specific pneu-
mococcal antigen testing could potentially help assess the risk 
of noninvasive pneumococcal pneumonia in patients with 
COVID-19 [37]. Another limitation is that it was not possible 
to distinguish between coinfection and secondary bacterial in-
fection because the patients were only tested for the virus and 
had blood cultures taken when they first presented to the hos-
pital with their IPD episode. Finally, some patients, especially 
the frail and elderly, were not admitted to the hospital and died 
at home or in a care home [38]. Early in the pandemic, these 
cases were also not tested for SARS-CoV-2 and, since they were 
not hospitalized, would not have been investigated for bacte-
rial coinfections. In 1 case series, up to 50% of patients with 
COVID-19 who died had a secondary bacterial infection [26]; 
although consistent with our findings, S. pneumoniae was not 
identified as a cause.
Conclusions
The COVID-19 pandemic and the lockdown that followed 
to stop the spread of SARS-CoV-2 was associated with large 
declines in IPD across all age groups. Invasive pneumococcal 
disease/COVID-19 coinfections were rare but associated with 
high CFRs, mainly in older adults. Secondary COVID-19 in 
Table 2. Incidence and Incidence Rate Ratios of Invasive Pneumococcal Disease and COVID-19 Between February and June 2020 (5 Months) in England
Age Group n (Incidence per 100 000) Incidence Rate Ratio [95% CI] P
IPD cases, February to June 2019    
 <16 years 134 (1.25) .44 [.37–.53] <.001
 16–64 years 986 (2.81) 1.00 [Base]  
 65–84 years 923 (10.47) 3.72 [3.40–4.07] <.001
 ≥85 years 397 (29.08) 10.34 [8.99–11.35] <.001
 Total 2440 (4.36) …
IPD cases, February to June 2020    
 <16 years 78 (0.72) .60 [.47–.76] <.001
 16–64 years 423 (1.20) 1.00 [Base]  
 65–84 years 445 (4.97) 4.12 [3.61–4.71] <.001
 ≥85 years 191 (13.67) 11.35 [9.57–13.46] <.001
 Total 1137 (2.02) …
SARS-CoV-2 cases, February to June 2020    
 <16 years 2252 (20.82) .09 [.08–.09] <.001
 16–64 years 82 967 (236.26) 1.00 [Base]  
 65–84 years 46 373 (517.75) 2.19 [2.16–2.21] <.001
 ≥85 years 29 294 (2096.85) 8.71 [8.60–8.83]
 Total 160 886 (285.83) …
 n (%) Rate Ratio [95% CI]  
IPD/COVID-19 coinfections in SARS-CoV-2–positive individuals    
 <16 years 0 (—) …  
 16–64 years 15 (0.018) 1.00 [Base]  
 65–84 years 14 (0.030) 1.67 [0.81–3.46] .16
 ≥85 years 11 (0.038) 2.08 [0.95–4.52] .06
 Total 40 (0.025) …
IPD/COVID-19 coinfections in patients with IPD    
 <16 years 0 (—) …  
 16–64 years 15 (3.6) 1.00 [Base]  
 65–84 years 14 (3.2) 0.89 [0.43–1.82] .74
 ≥85 years 11 (5.8) 1.62 [0.76–3.47] .21
 Total 40 (3.5) …
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patients hospitalized with IPD was also associated with high 
CFRs, highlighting the importance of enforcing stringent 
infection-control practices in hospitals, especially for vul-
nerable patients such as the frail and elderly. The rarity and 
broad age range of cases with IPD/COVID-19 coinfections 
as well as the wide range of responsible pneumococcal sero-
types do not support extending current recommendations 
for any of the available pneumococcal vaccines during the 
COVID-19 pandemic. Eligible individuals should continue to 
receive pneumococcal vaccines according to local and national 
recommendations.
Notes
Acknowledgments. Public Health England (PHE) has legal permis-
sion, provided by Regulation 3 of The Health Service (Control of Patient 
Information) Regulations 2002, to process patient confidential information 
for national surveillance of communicable diseases. This includes PHE’s re-
sponsibility to monitor the safety and effectiveness of vaccines, and as such, 
individual patient consent is not required.
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Figure 4. Timeline of IPD and COVID-19 infections in patients who developed both infections within 28 days between 1 February and 30 June 2020 (5 months) in England. 
The teal bars on the left of the vertical line (day 0) depict the interval in days between IPD and COVID-19 diagnosis, while the teal bars on the right of the vertical line (day 
0) depict the interval in days between COVID-19 and IPD diagnosis (those within 2 days of each other were considered IPD/COVID-19 coinfections). The dashed red lines 
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